Global Low Back Pain Drug Pipeline Trends 2019: Discovery, Pre-clinical, Clinical, In Approval Therapeutics, Companies and Markets
High levels of pipeline activity are being observed in Low Back Pain treatment during 2019. Clinical development activities are being undertaken by more than 25 companies including Ache Laboratorios Farmaceuticos S.A, Adynxx Inc, Allodynic Therapeutics LLC, AnGes Inc, Array BioPharma Inc and others.
A Significant contribution to the Low Back Pain pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Low Back Pain pipeline included 27 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Low Back Pain condition and increased access to investments is encouraging growth of Low Back Pain drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Low Back Pain drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Low Back Pain therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Low Back Pain pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Low Back Pain. Further, orphan drug status, fast track designation, grants awarded and other special status for Low Back Pain pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Low Back Pain pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Low Back Pain Pipeline candidates-
A Significant contribution to the Low Back Pain pipeline is being observed from emerging companies opting for new approaches to clinical development strategy. The early stage and late-stage Low Back Pain pipeline included 27 compounds, driven by increasing number of targeted therapies. Progress is being made in accelerating compounds into advanced stages. However, fluctuating trends are being observed in average duration across three phases.
Increased understanding of underlying causes of Low Back Pain condition and increased access to investments is encouraging growth of Low Back Pain drug pipeline. However, despite high levels of pipeline activity, increasing clinical trial costs and decreasing drug approval rates is requiring companies to focus more on understanding clinical development pipeline compounds.
The research study is structured to provide clear and actionable insights into Low Back Pain drug pipeline for companies to optimize spending levels by understanding competition, their pipeline products and prospect of further advances over the next few years.
The report addresses the discovery, research and pre-clinical stage active Low Back Pain therapeutic candidates. Further, drugs in clinical stage including phase 1, phase 2, phase 3 and pre-registration phases are also analyzed.
The current report examines the current Low Back Pain pipeline along with current development status, regulatory progress, mechanism of action, route of administration, collaborating companies, sponsors, molecule type, and research/discovery details.
In addition to drug overview, recent developments, the report also provides mechanism of action, Pre-clinical trial details and Clinical trial details for each of the drug candidates of Low Back Pain. Further, orphan drug status, fast track designation, grants awarded and other special status for Low Back Pain pipeline compounds are also included.
This study was produced independently by VPAResearch from our proprietary databases, primarily to assist users to develop in-depth understanding of 2019 Low Back Pain pipeline and formulate effective research and development strategies.
RESEARCH METHODOLOGY
Our integrated data reports are built through robust research methodology to ensure our users can build on the insights and data accuracy for their expansion plans. Both primary and secondary research methods are used with stringent quality checks at each stage to evaluate trends, analysis and forecasts.
Scope of the Research
Low Back Pain Pipeline candidates-
- Pre-clinical Phase: Discovery, research, pre-clinical
- Early Phase: Phase 1 and Phase 2 Low Back Pain drugs
- Late phase: Phase 3 and in-approval Low Back Pain drugs
- Company overview
- Snapshot
- Low Back Pain therapeutic treatment activities
- Snapshot
- Drug Name
- Alternative Names
- Company
- Originator
- Phase
- Molecule Type
- Orphan Drug Status
- Drug Overview
- Mechanism of Action
- Current Status
- Trial Details
- Pre-clinical trials for each drug candidate
- Clinical trials for each drug candidate
1 TABLE OF CONTENTS
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Low Back Pain- Disease Overview
2.2 Low Back Pain- Pipeline Snapshot
2.3 Low Back Pain- Pipeline Drugs by Phase
2.4 Low Back Pain- Pipeline Drugs by Company
2.5 Low Back Pain- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Ache Laboratorios Farmaceuticos S.A Low Back Pain Drug Pipeline, H2- 2019
3.2 Adynxx Inc Low Back Pain Drug Pipeline, H2- 2019
3.3 Allodynic Therapeutics LLC Low Back Pain Drug Pipeline, H2- 2019
3.4 AnGes Inc Low Back Pain Drug Pipeline, H2- 2019
3.5 Array BioPharma Inc Low Back Pain Drug Pipeline, H2- 2019
3.6 Axsome Therapeutics Inc Low Back Pain Drug Pipeline, H2- 2019
3.7 Camurus Low Back Pain Drug Pipeline, H2- 2019
3.8 Daewon Pharmaceutical Low Back Pain Drug Pipeline, H2- 2019
3.9 Egalet Corporation Low Back Pain Drug Pipeline, H2- 2019
3.10 Frontier Biotechnologies Inc Low Back Pain Drug Pipeline, H2- 2019
3.11 Gador SA Low Back Pain Drug Pipeline, H2- 2019
3.12 Hisamitsu Pharmaceutical Co Inc Low Back Pain Drug Pipeline, H2- 2019
3.13 Imbrium Therapeutics Low Back Pain Drug Pipeline, H2- 2019
3.14 Immune Pharmaceuticals Inc Low Back Pain Drug Pipeline, H2- 2019
3.15 Inspyr Therapeutics Inc Low Back Pain Drug Pipeline, H2- 2019
3.16 MD Biosciences Low Back Pain Drug Pipeline, H2- 2019
3.17 Mesoblast Ltd Low Back Pain Drug Pipeline, H2- 2019
3.18 Navipharm Co Ltd Low Back Pain Drug Pipeline, H2- 2019
3.19 Nektar Therapeutics Low Back Pain Drug Pipeline, H2- 2019
3.20 Neurana Pharmaceuticals Inc Low Back Pain Drug Pipeline, H2- 2019
3.21 Pacira Pharmaceuticals Inc Low Back Pain Drug Pipeline, H2- 2019
3.22 Pfizer Inc Low Back Pain Drug Pipeline, H2- 2019
3.23 Regeneron Pharmaceuticals Low Back Pain Drug Pipeline, H2- 2019
3.24 SpineThera Inc Low Back Pain Drug Pipeline, H2- 2019
3.25 Stayble Therapeutics Low Back Pain Drug Pipeline, H2- 2019
3.26 Therapix Biosciences Ltd Low Back Pain Drug Pipeline, H2- 2019
3.27 WEX Pharmaceuticals Inc Low Back Pain Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Low Back Pain- Phase 1 Drug Details
4.2 Low Back Pain- Phase 1 Drug Overview
4.3 Low Back Pain- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Low Back Pain- Phase 2 Drug Details
5.2 Low Back Pain- Phase 2 Drug Overview
5.3 Low Back Pain- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Low Back Pain- Phase 3 Drug Details
6.2 Low Back Pain- Phase 3 Drug Overview
6.3 Low Back Pain- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Low Back Pain- Pre-clinical Phase Drug Details
7.2 Low Back Pain- Pre-clinical Phase Drug Overview
7.3 Low Back Pain- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
1.1 List of Tables
1.2 List of Figures
2 EXECUTIVE SUMMARY
2.1 Low Back Pain- Disease Overview
2.2 Low Back Pain- Pipeline Snapshot
2.3 Low Back Pain- Pipeline Drugs by Phase
2.4 Low Back Pain- Pipeline Drugs by Company
2.5 Low Back Pain- Pipeline Drugs by Mechanism of Action
3 COMPANY WISE PIPELINE ANALYSIS
3.1 Ache Laboratorios Farmaceuticos S.A Low Back Pain Drug Pipeline, H2- 2019
3.2 Adynxx Inc Low Back Pain Drug Pipeline, H2- 2019
3.3 Allodynic Therapeutics LLC Low Back Pain Drug Pipeline, H2- 2019
3.4 AnGes Inc Low Back Pain Drug Pipeline, H2- 2019
3.5 Array BioPharma Inc Low Back Pain Drug Pipeline, H2- 2019
3.6 Axsome Therapeutics Inc Low Back Pain Drug Pipeline, H2- 2019
3.7 Camurus Low Back Pain Drug Pipeline, H2- 2019
3.8 Daewon Pharmaceutical Low Back Pain Drug Pipeline, H2- 2019
3.9 Egalet Corporation Low Back Pain Drug Pipeline, H2- 2019
3.10 Frontier Biotechnologies Inc Low Back Pain Drug Pipeline, H2- 2019
3.11 Gador SA Low Back Pain Drug Pipeline, H2- 2019
3.12 Hisamitsu Pharmaceutical Co Inc Low Back Pain Drug Pipeline, H2- 2019
3.13 Imbrium Therapeutics Low Back Pain Drug Pipeline, H2- 2019
3.14 Immune Pharmaceuticals Inc Low Back Pain Drug Pipeline, H2- 2019
3.15 Inspyr Therapeutics Inc Low Back Pain Drug Pipeline, H2- 2019
3.16 MD Biosciences Low Back Pain Drug Pipeline, H2- 2019
3.17 Mesoblast Ltd Low Back Pain Drug Pipeline, H2- 2019
3.18 Navipharm Co Ltd Low Back Pain Drug Pipeline, H2- 2019
3.19 Nektar Therapeutics Low Back Pain Drug Pipeline, H2- 2019
3.20 Neurana Pharmaceuticals Inc Low Back Pain Drug Pipeline, H2- 2019
3.21 Pacira Pharmaceuticals Inc Low Back Pain Drug Pipeline, H2- 2019
3.22 Pfizer Inc Low Back Pain Drug Pipeline, H2- 2019
3.23 Regeneron Pharmaceuticals Low Back Pain Drug Pipeline, H2- 2019
3.24 SpineThera Inc Low Back Pain Drug Pipeline, H2- 2019
3.25 Stayble Therapeutics Low Back Pain Drug Pipeline, H2- 2019
3.26 Therapix Biosciences Ltd Low Back Pain Drug Pipeline, H2- 2019
3.27 WEX Pharmaceuticals Inc Low Back Pain Drug Pipeline, H2- 2019
4 PHASE 1 PIPELINE DRUG DETAILS
4.1 Low Back Pain- Phase 1 Drug Details
4.2 Low Back Pain- Phase 1 Drug Overview
4.3 Low Back Pain- Phase 1 Mechanism of Action
4.4 Current Status
4.5 Trial Details
5 PHASE 2 PIPELINE DRUG DETAILS
5.1 Low Back Pain- Phase 2 Drug Details
5.2 Low Back Pain- Phase 2 Drug Overview
5.3 Low Back Pain- Phase 2 Mechanism of Action
5.4 Current Status
5.5 Trial Details
6 PHASE 3 PIPELINE DRUG DETAILS
6.1 Low Back Pain- Phase 3 Drug Details
6.2 Low Back Pain- Phase 3 Drug Overview
6.3 Low Back Pain- Phase 3 Drug Mechanism of Action
6.4 Current Status
6.5 Trial Details
7 PRE-CLINICAL PHASE PIPELINE DRUG DETAILS
7.1 Low Back Pain- Pre-clinical Phase Drug Details
7.2 Low Back Pain- Pre-clinical Phase Drug Overview
7.3 Low Back Pain- Pre-clinical Phase Drug Mechanism of Action
7.4 Current Status
7.5 Trial Details
8 RECENT NEWS AND DEVELOPMENTS
9 APPENDIX
9.1 About VPAResearch
9.2 Sources and Research Methodology
